AlphaStocks
3.7
Weak

REGENERON PHARMACEUTICALS, INC. (REGN)

Health Care / Biotechnology

S&P 500

$610.05

Scores poorly across most models. Proceed with caution.

Weak

Score based on 5 of 5 models — high confidence

#892out of 1123 in Health Care

Is REGENERON PHARMACEUTICALS, INC. a Good Investment in 2026?

REGENERON PHARMACEUTICALS, INC. (REGN) scores 3.7 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates REGENERON PHARMACEUTICALS, INC. as Attractive (5/9). The Greenblatt Magic Formula model is the least favorable, rating it Neutral. REGENERON PHARMACEUTICALS, INC. currently trades below its estimated fair value of $793, suggesting potential upside. REGENERON PHARMACEUTICALS, INC. ranks #892 out of 1123 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E14.7ROE12.7Market Cap66B

Estimated Fair Value

$792.5223% below

Fair value above market price. P/E of 15x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

24% above fair value

Lynch

Neutral

PEG 1.0 · Fast Grower

Greenblatt

Neutral

Bottom half (rank 67%)

Frequently Asked Questions

Is REGENERON PHARMACEUTICALS, INC. (REGN) a good investment?
Based on AlphaStocks' composite analysis, REGENERON PHARMACEUTICALS, INC. (REGN) scores 3.7 out of 10, earning a Weak rating. This score is below average, suggesting caution. Fair value above market price. P/E of 15x is moderate for this quality level.
What is REGENERON PHARMACEUTICALS, INC.'s Piotroski F-Score?
REGENERON PHARMACEUTICALS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is REGN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $793, REGN appears undervalued. The stock currently trades 23% below its estimated fair value. Fair value above market price. P/E of 15x is moderate for this quality level.
How does REGN compare to other Health Care stocks?
REGENERON PHARMACEUTICALS, INC. ranks #892 out of 1123 stocks in the Health Care sector, placing it in the top 79% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about REGN?
AlphaStocks evaluates REGN using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 3.7/10.

Similar Stocks

BFAMPARRAZN

Compare REGN with

REGN vs BFAMREGN vs PARRREGN vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer